Treatment Response to Xiaflex for Men With Peyronie's Disease

Treatment Response to Xiaflex Based on Ultrasound Characterization of Plaque for Men With Peyronie's Disease

The purpose of this research study is to develop a database of patients with Peyronie's disease who are treated at the University of Miami. The collected data will help the researchers to better understand Peyronie's disease and its response to therapy.

Inclusion Criteria:

• Age ≥18 years
• Able to provide informed consent
• A stable relationship for ≥3 months
• PD symptoms with evidence of stable disease as determined by the investigator
• Penile curvature deformity of >30° to <90°
• Has not had previous surgery for PD
• Has not had previous therapy with Xiaflex for PD

Exclusion Criteria:

• Ventral plaque
• Active phase PD
• Actively on anticoagulation during time frame of injections
• Aspirin 81mg will be eligible for therapy
• Hour glass deformity
• Previous allergic reaction to Xiaflex
• Unwilling to participate
• Medically unfit for sexual intercourse as deemed by the principal investigator
• Patients scheduled to undergo an elective medical procedure during the investigation timeframe that will interfere with Xiaflex injection cycles as deemed by the PI